Segment & Geographic Data
Quant-Grade Normalized (live API)
API & CSV Delivery
Cvrx Inc's Business Segments
Cvrx Inc's reported revenue by business segment and by geographic region, quarterly and annual, normalized against the consolidated income statement. Free below: the top 3 rows per table, this quarter and this fiscal year. Subscriber access adds the full segment history and operating income by segment.
Reportable Segments
-
Largest Segment
-
Total Revenue
$ 14
Countrys Reported
1
Revenue Share by Country -
- US98.3%
Revenue by Geographic Country -
| Country | Revenue (Millions) | % of Total |
|---|---|---|
| US | $ 14 | 98.3% |
Description of Cvrx Inc
CVRx Inc. is a medical device company based in Minneapolis, Minnesota. The company specializes in developing implantable technology for the treatment of cardiovascular diseases such as hypertension and heart failure.
CVRx's flagship product is the Barostim Neo System, which is designed to treat hypertension, also known as high blood pressure. The system consists of an implantable pulse generator (IPG) and a lead that is placed near the carotid artery in the neck. The IPG delivers electrical signals to the lead, which in turn stimulates the baroreceptors in the carotid artery. This stimulation triggers a cascade of physiological responses that help regulate blood pressure.
The Barostim Neo System received CE Mark approval in Europe in 2002 and has been commercially available in select European countries since then. In 2019, the system received FDA approval for the treatment of heart failure in the United States.
CVRx Inc. was founded in 2001 by Dr. Robert Kieval, who serves as the Chief Science Officer of the company. The company's mission is to improve the quality of life for patients suffering from cardiovascular diseases and to reduce the burden on healthcare systems.
In addition to the Barostim Neo System, CVRx is actively involved in clinical research and development of other potential therapies for cardiovascular diseases. The company has conducted multiple clinical trials to evaluate the efficacy and safety of its products. These trials have shown promising results, demonstrating the potential of CVRx's technology to improve patient outcomes.
CVRx Inc. operates with a team of experienced professionals, including scientists, engineers, clinicians, and business executives. The company has a strong focus on innovation and invests heavily in research and development to continuously improve its products and expand its market reach.
The company has partnerships with leading medical institutions and research organizations worldwide, collaborating on clinical studies and sharing knowledge to further advance the field of cardiovascular medicine. CVRx also actively engages with healthcare providers and regulatory authorities to ensure compliance with standards and regulations.
CVRx Inc. has a global presence, with offices and distribution networks in Europe, Asia, and the Americas. The company works closely with healthcare professionals and patients to provide training and support, ensuring the safe and effective use of its products.
Overall, CVRx Inc. is a pioneering medical device company that has revolutionized the treatment of cardiovascular diseases with its innovative implantable technology. With its commitment to research, development, and collaboration, CVRx continues to be at the forefront of improving patient outcomes and transforming cardiovascular care.
CVRx's flagship product is the Barostim Neo System, which is designed to treat hypertension, also known as high blood pressure. The system consists of an implantable pulse generator (IPG) and a lead that is placed near the carotid artery in the neck. The IPG delivers electrical signals to the lead, which in turn stimulates the baroreceptors in the carotid artery. This stimulation triggers a cascade of physiological responses that help regulate blood pressure.
The Barostim Neo System received CE Mark approval in Europe in 2002 and has been commercially available in select European countries since then. In 2019, the system received FDA approval for the treatment of heart failure in the United States.
CVRx Inc. was founded in 2001 by Dr. Robert Kieval, who serves as the Chief Science Officer of the company. The company's mission is to improve the quality of life for patients suffering from cardiovascular diseases and to reduce the burden on healthcare systems.
In addition to the Barostim Neo System, CVRx is actively involved in clinical research and development of other potential therapies for cardiovascular diseases. The company has conducted multiple clinical trials to evaluate the efficacy and safety of its products. These trials have shown promising results, demonstrating the potential of CVRx's technology to improve patient outcomes.
CVRx Inc. operates with a team of experienced professionals, including scientists, engineers, clinicians, and business executives. The company has a strong focus on innovation and invests heavily in research and development to continuously improve its products and expand its market reach.
The company has partnerships with leading medical institutions and research organizations worldwide, collaborating on clinical studies and sharing knowledge to further advance the field of cardiovascular medicine. CVRx also actively engages with healthcare providers and regulatory authorities to ensure compliance with standards and regulations.
CVRx Inc. has a global presence, with offices and distribution networks in Europe, Asia, and the Americas. The company works closely with healthcare professionals and patients to provide training and support, ensuring the safe and effective use of its products.
Overall, CVRx Inc. is a pioneering medical device company that has revolutionized the treatment of cardiovascular diseases with its innovative implantable technology. With its commitment to research, development, and collaboration, CVRx continues to be at the forefront of improving patient outcomes and transforming cardiovascular care.
CVRx, Inc. is a medical device company focused on developing innovative therapies for patients with cardiovascular diseases. Their primary area of expertise lies in the treatment of hypertension and heart failure through advanced device technologies. Below are the segments, products, and services offered by CVRx.
Segments
1. Hypertension Management:
CVRx is particularly recognized for its contributions to the management of severe hypertension (high blood pressure) that is resistant to standard treatment modalities.
2. Heart Failure Treatment:
The companys offerings include solutions aimed at patients with heart failure, focusing on improving cardiac function and overall patient outcomes.
3. Neuromodulation and Electrical Stimulation:
With developments in neuromodulation devices, CVRx explores innovative methods to modulate nerve activity related to cardiovascular functions.
Products
1. Barostim Neo:
This is CVRxs flagship product and represents a breakthrough in the treatment of resistant hypertension. Barostim Neo is a neuromodulation device designed to target the baroreceptors in the carotid arteries. By stimulating these sensory nerves, the device helps regulate blood pressure through the autonomic nervous system. It is minimally invasive and can be implanted using catheter-based technology.
- Indications:
- Treatment of adults with high blood pressure that isn’t well controlled with medications.
- Mechanism:
- The device stimulates baroreceptors to send signals to the brain, which in turn helps lower blood pressure without relying solely on pharmaceuticals.
2. Remote Monitoring System:
To enhance patient care, CVRx may offer remote monitoring technologies that allow physicians to track the device’s performance and the patient’s condition. This system can provide real-time data on blood pressure levels and device functionality.
3. Patient Education and Support:
Alongside their medical devices, CVRx is committed to patient education about hypertension management, treatment options, and lifestyle changes. This involves providing materials and resources to help patients understand their conditions and the importance of adherence to prescribed therapies.
Services
1. Clinical Support:
CVRx provides training and support for healthcare professionals to ensure they are well-versed in the use of the Barostim Neo device. This may include in-person training, digital resources, and ongoing education to optimize patient outcomes.
2. Patient-Centric Programs:
These programs are designed to assist patients in navigating their treatment journey. This might include follow-ups, telehealth services, and personalized support to ensure compliance and effectiveness of the treatment plan.
3. Regulatory and Reimbursement Assistance:
CVRx works with healthcare providers to navigate the complexities of insurance reimbursement for their devices. They may provide guidance on coding, billing, and securing approval for treatment.
4. Research and Development:
As part of its mission to provide innovative treatment solutions, CVRx engages in ongoing research and clinical trials. They may collaborate with academic institutions and clinical organizations to explore new therapies and improve existing ones.
5. Global Expansion Initiatives:
To serve more patients globally, CVRx may engage in strategic partnerships, collaborations, and regulatory processes to expand the availability of their products into new markets.
Conclusion
CVRx, Inc. stands at the forefront of cardiovascular treatment innovation, particularly in managing conditions like hypertension and heart failure through their proprietary devices and supportive services. Their commitment to enhancing patient care through advanced technology and comprehensive support systems underscores their role in transforming cardiovascular healthcare.
Segments
1. Hypertension Management:
CVRx is particularly recognized for its contributions to the management of severe hypertension (high blood pressure) that is resistant to standard treatment modalities.
2. Heart Failure Treatment:
The companys offerings include solutions aimed at patients with heart failure, focusing on improving cardiac function and overall patient outcomes.
3. Neuromodulation and Electrical Stimulation:
With developments in neuromodulation devices, CVRx explores innovative methods to modulate nerve activity related to cardiovascular functions.
Products
1. Barostim Neo:
This is CVRxs flagship product and represents a breakthrough in the treatment of resistant hypertension. Barostim Neo is a neuromodulation device designed to target the baroreceptors in the carotid arteries. By stimulating these sensory nerves, the device helps regulate blood pressure through the autonomic nervous system. It is minimally invasive and can be implanted using catheter-based technology.
- Indications:
- Treatment of adults with high blood pressure that isn’t well controlled with medications.
- Mechanism:
- The device stimulates baroreceptors to send signals to the brain, which in turn helps lower blood pressure without relying solely on pharmaceuticals.
2. Remote Monitoring System:
To enhance patient care, CVRx may offer remote monitoring technologies that allow physicians to track the device’s performance and the patient’s condition. This system can provide real-time data on blood pressure levels and device functionality.
3. Patient Education and Support:
Alongside their medical devices, CVRx is committed to patient education about hypertension management, treatment options, and lifestyle changes. This involves providing materials and resources to help patients understand their conditions and the importance of adherence to prescribed therapies.
Services
1. Clinical Support:
CVRx provides training and support for healthcare professionals to ensure they are well-versed in the use of the Barostim Neo device. This may include in-person training, digital resources, and ongoing education to optimize patient outcomes.
2. Patient-Centric Programs:
These programs are designed to assist patients in navigating their treatment journey. This might include follow-ups, telehealth services, and personalized support to ensure compliance and effectiveness of the treatment plan.
3. Regulatory and Reimbursement Assistance:
CVRx works with healthcare providers to navigate the complexities of insurance reimbursement for their devices. They may provide guidance on coding, billing, and securing approval for treatment.
4. Research and Development:
As part of its mission to provide innovative treatment solutions, CVRx engages in ongoing research and clinical trials. They may collaborate with academic institutions and clinical organizations to explore new therapies and improve existing ones.
5. Global Expansion Initiatives:
To serve more patients globally, CVRx may engage in strategic partnerships, collaborations, and regulatory processes to expand the availability of their products into new markets.
Conclusion
CVRx, Inc. stands at the forefront of cardiovascular treatment innovation, particularly in managing conditions like hypertension and heart failure through their proprietary devices and supportive services. Their commitment to enhancing patient care through advanced technology and comprehensive support systems underscores their role in transforming cardiovascular healthcare.